Core Viewpoint - The company has signed a strategic cooperation framework agreement with Xi'an New Tong Pharmaceutical Research Co., Ltd. to collaborate in the fields of innovative drug research and development and contract development and manufacturing organization (CDMO) projects for a duration of ten years [1] Group 1: Agreement Details - The agreement aims to enhance the company's competitiveness in the CDMO business through complementary advantages [1] - This framework agreement does not involve specific transactions and will not have a significant impact on the company's operating performance for the current year [1] - The impact on future operating performance will depend on the signing and implementation of specific project agreements [1] Group 2: Intellectual Property and Responsibilities - During the collaboration, research results and related intellectual property will belong to Xi'an New Tong [1] - The company commits to using the relevant technologies and processes only within the scope of the cooperation and guarantees that the development results do not infringe on third-party rights [1] Group 3: Risks and Uncertainties - The specific cooperation matters will require separate agreements, and there is uncertainty regarding the ability to achieve substantial cooperation [1] - The progress of the collaboration may be affected by industry policies, market conditions, and other force majeure factors [1]

Core Viewpoint - The company, Pro Pharmaceutical (000739), has signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development and custom manufacturing projects (CDMO projects) [1] Group 1 - The collaboration aims to expand the company's CDMO business and enhance its competitiveness in the CDMO sector [1]

证券代码：000739 证券简称：普洛药业 公告编号：2026-02 1.本次公司与合作方签署的《战略合作框架协议》，本着平等互利、优 势互补的原则，经友好协商，就研发与外包定制生产项目的合作关系达成共 识。具体项目合作事宜将由双方另行签署具体协议。 2.本次签署的《战略合作框架协议》对公司本年度经营业绩不会构成 重大影响，对公司未来年度经营业绩的影响将视公司与合作方后续签订的 具体项目协议以及实施情况而确定。 3.公司不存在最近三年披露的框架协议无进展或进展未达预期的情况。 一、战略框架协议签署概况 普洛药业股份有限公司(以下简称"公司"或"乙方")与西安新通药 物研究股份有限公司（以下简称"西安新通"或"甲方"）本着平等互利、 优势互补的原则，于近日签订了《战略合作框架协议》，旨在开展创新药 研发与外包定制生产项目（以下简称"CDMO项目"）的长期合作。 二、战略合作框架协议合作方基本情况 普洛药业股份有限公司 关于签署战略合作框架协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 本次签署的《战略合作框架协议》仅为框架性协议，不涉及实质性交 易， ...

Core Viewpoint - The company has signed a strategic cooperation framework agreement with Xi'an New Tong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development as well as outsourced custom manufacturing projects [1] Group 1: Agreement Details - The agreement is a framework agreement and does not involve substantial transactions or constitute a major asset restructuring [1] - The collaboration is expected to benefit the company's CDMO (Contract Development and Manufacturing Organization) business expansion and enhance its competitive edge [1] Group 2: Financial Impact - The agreement is not expected to have a significant impact on the company's operating performance for the current fiscal year [1] - Future performance implications will depend on subsequent specific project agreements and their implementation [1]

格隆汇1月5日丨普洛药业(000739.SZ)公布，截至2025年12月31日，公司通过回购专用证券账户以集中 竞价方式回购公司股份20,370,000股，占公司目前总股本的1.76%，最高成交价为16.85元/股，最低成交 价为15.71元/股，成交总金额为332,025,552.50元（不含交易费用）。本次回购符合公司回购股份方案及 相关法律法规的要求。 ...

（记者 王晓波） 每经AI快讯，普洛药业1月5日晚间发布公告称，截至2025年12月31日，公司通过回购专用证券账户以 集中竞价方式回购公司股份2037万股，占公司目前总股本的1.76%，最高成交价为16.85元/股，最低成 交价为15.71元/股，成交总金额约为3.32亿元。 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 ...

根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9号——回购股份》等相关规定，公司应当在每个月的前三个交易日内，公告截 至上月末的回购进展情况。现将公司回购股份进展情况公告如下： 一、回购股份的进展情况 证券代码：000739 证券简称：普洛药业 公告编号：2026-01 普洛药业股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）于2025年11月18日召开第九届 董事会第十七次会议审议通过了《关于2025年第二次回购公司股份方案的议案》， 同意公司使用自有资金及金融机构回购贷款通过深圳证券交易所交易系统以集 中竞价交易方式回购公司股份，本次回购股份拟用于股权激励或员工持股计划。 本次回购股份价格不超过人民币23元/股，回购资金总额：不低于人民币18,000 万元（含）且不超过人民币36,000万元（含）。具体回购股份的数量和金额以回 购期限届满或者回购股份实施完毕时实际回购的股份数量和金额为准。回购期限 为自董事会审议通过回购股份方案之日起12个月内。具体内容 ...

Group 1 - The article highlights the development of Hengdian, known as the "Oriental Hollywood," which has become the world's largest film shooting base, generating an annual output value exceeding 35 billion yuan [5][10]. - Hengdian Group, founded 50 years ago, has diversified into various sectors including film and tourism, electronics, and pharmaceuticals, with total assets exceeding 100 billion yuan and six listed companies under its umbrella [5][15][17]. - The founder, Xu Wenrong, and his son, Xu Yong'an, are described as low-profile billionaires, emphasizing that the wealth of Hengdian Group belongs to the collective rather than individuals [6][18]. Group 2 - Hengdian's film industry strategy includes offering free shooting locations to attract film crews, which has led to significant growth in related services such as accommodation and dining, with the film industry generating 15.7 billion yuan in 2020 alone [10][11]. - The Hengdian Film City is projected to receive 15.24 million visitors in 2023, with revenues of 2.638 billion yuan, and 13.93 million visitors in 2024, with revenues of 2.867 billion yuan [11][12]. - Hengdian Film's revenue for 2024 is expected to be 1.971 billion yuan, with nearly 90% coming from cinema operations, while film investment and production contribute 10.3% [12]. Group 3 - Hengdian Group's assets include a general airport and a water plant, with a total revenue of 94.2 billion yuan in 2024 and a net profit of 3.124 billion yuan [17][18]. - The group has a unique corporate structure where ownership is held by community organizations, which has drawn interest from economists [19][20]. - The company is facing challenges in its magnetic materials sector, with market share declining to around 30%, and is adapting to the rise of short dramas in the film industry [24][25]. Group 4 - Hengdian Group is actively seeking transformation, with its photovoltaic sector achieving revenue of 11.47 billion yuan in 2025, a 43.6% increase, becoming a key business segment [25]. - The overall development of Hengdian has significantly improved local income levels, with residents' average annual income reaching 70,000 yuan [25].

证券代码：000739 证券简称：普洛药业 公告编号：2025-79 普洛药业股份有限公司 关于对下属公司担保的进展公告 二、担保事项履行的审议程序 公司于 2025 年 3 月 7 日、2025 年 4 月 17 日分别召开了第九届董事会第十 一次会议及 2024 年年度股东大会，审议通过了《关于对下属公司提供担保预计 的议案》，为下属 10 家子公司及孙公司在银行等金融机构的融资提供不超过人 民币 71 亿元的融资担保。本次对外担保额度授权期限为公司 2024 年年度股东大 会审议通过之日起至 2025 年年度股东大会召开之日止。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 1、2025 年 12 月 11 日，普洛药业股份有限公司（以下简称"公司"）与中 国银行股份有限公司东阳支行（以下简称"中国银行"）签订《保证合同》（合 同编号：横店 2025 年人保字 213 号），同意为公司全资子公司浙江普洛家园药 业有限公司（以下简称"家园药业"）与中国银行签署的《商业汇票承兑协议》 （合同编号：横店 2025 年人承字 213 号）中的 ...

Core Viewpoint - Hengdian Group, known for its film and tourism industry, has diversified into various sectors including electronics and pharmaceuticals, with a total asset exceeding 100 billion yuan and a revenue of 942 billion yuan in 2024 [5][14]. Group 1: Film and Tourism Industry - Hengdian has become the largest film shooting base globally, generating over 35 billion yuan annually from its film and tourism industry [4]. - The company offers free filming locations to attract film crews, resulting in a loss of approximately 20 million yuan annually, but this strategy has significantly boosted the local film service and hospitality industries [8]. - In 2023 and 2024, Hengdian Film City is expected to receive 15.24 million and 13.93 million visitors, with revenues of 2.638 billion yuan and 2.867 billion yuan respectively [9]. Group 2: Business Diversification - Hengdian Group has evolved from a silk factory to a conglomerate with interests in film, electronics, pharmaceuticals, and modern services, holding six publicly listed companies [5][12]. - The electronics sector, particularly magnetic materials, once dominated the market but has seen a decline in market share to around 30% [23]. - The pharmaceutical sector, represented by Prolo Pharmaceutical, has been a significant contributor to the group's revenue since its inception [12]. Group 3: Financial Performance - In 2024, Hengdian Group reported a revenue of 942 billion yuan, with total assets reaching 1,039.78 billion yuan and a net profit of 3.124 billion yuan [14]. - The group has also ventured into financial services, holding a 4.99% stake in Zheshang Bank and recently listing Nanhua Futures on the Hong Kong Stock Exchange [14]. Group 4: Ownership Structure - Hengdian Group operates under a unique corporate structure where ownership is held by community organizations rather than individual shareholders, emphasizing collective wealth creation [21][22]. - The founder, Xu Wenrong, has consistently refused to appear on wealth rankings, asserting that the group's wealth belongs to the collective rather than individuals [16][21]. Group 5: Challenges and Future Outlook - The rise of short dramas poses a challenge to traditional film productions, prompting Hengdian to adapt by developing vertical filming spaces [23]. - The group is investing in new projects, including a 12GW battery production facility and the expansion of Hengdian Airport, with total investments in ongoing projects amounting to 11.678 billion yuan [23][24].